SE0100569D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0100569D0
SE0100569D0 SE0100569A SE0100569A SE0100569D0 SE 0100569 D0 SE0100569 D0 SE 0100569D0 SE 0100569 A SE0100569 A SE 0100569A SE 0100569 A SE0100569 A SE 0100569A SE 0100569 D0 SE0100569 D0 SE 0100569D0
Authority
SE
Sweden
Prior art keywords
new compounds
active compounds
preparation
compounds
new
Prior art date
Application number
SE0100569A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100569A priority Critical patent/SE0100569D0/xx
Publication of SE0100569D0 publication Critical patent/SE0100569D0/xx
Priority to CNB028052471A priority patent/CN1294131C/zh
Priority to BR0206935-0A priority patent/BR0206935A/pt
Priority to NZ526783A priority patent/NZ526783A/en
Priority to KR10-2003-7010874A priority patent/KR20030084935A/ko
Priority to HU0303254A priority patent/HUP0303254A2/hu
Priority to IL15678102A priority patent/IL156781A0/xx
Priority to EEP200300400A priority patent/EE200300400A/xx
Priority to US10/468,604 priority patent/US7345050B2/en
Priority to HK05102865.3A priority patent/HK1070071B/xx
Priority to PCT/SE2002/000271 priority patent/WO2002065979A2/en
Priority to SK1025-2003A priority patent/SK10252003A3/sk
Priority to JP2002565540A priority patent/JP4475869B2/ja
Priority to EP02711620A priority patent/EP1373266A2/en
Priority to CA002434648A priority patent/CA2434648A1/en
Priority to CZ20032235A priority patent/CZ20032235A3/cs
Priority to PL02363393A priority patent/PL363393A1/xx
Priority to MXPA03007320A priority patent/MXPA03007320A/es
Priority to RU2003121307/04A priority patent/RU2003121307A/ru
Priority to IS6868A priority patent/IS6868A/is
Priority to BG108070A priority patent/BG108070A/bg
Priority to ZA200306171A priority patent/ZA200306171B/xx
Priority to NO20033679A priority patent/NO20033679L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0100569A 2001-02-20 2001-02-20 New compounds SE0100569D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds
RU2003121307/04A RU2003121307A (ru) 2001-02-20 2002-02-18 (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета
PCT/SE2002/000271 WO2002065979A2 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
JP2002565540A JP4475869B2 (ja) 2001-02-20 2002-02-18 新規なピリミジン化合物
NZ526783A NZ526783A (en) 2001-02-20 2002-02-18 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes
KR10-2003-7010874A KR20030084935A (ko) 2001-02-20 2002-02-18 Ｃｎｓ 장애 및 당뇨병의 치료에 사용하기 위한(디아졸로-피리디닐)-피리미딘
HU0303254A HUP0303254A2 (hu) 2001-02-20 2002-02-18 Új pirimidinvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL15678102A IL156781A0 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes
EEP200300400A EE200300400A (et) 2001-02-20 2002-02-18 Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
US10/468,604 US7345050B2 (en) 2001-02-20 2002-02-18 Pyrimidine compounds
HK05102865.3A HK1070071B (en) 2001-02-20 2002-02-18 New pyrimidine compounds
CNB028052471A CN1294131C (zh) 2001-02-20 2002-02-18 新嘧啶化合物
SK1025-2003A SK10252003A3 (sk) 2001-02-20 2002-02-18 Pyrimidínové zlúčeniny
BR0206935-0A BR0206935A (pt) 2001-02-20 2002-02-18 Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
EP02711620A EP1373266A2 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
CA002434648A CA2434648A1 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
CZ20032235A CZ20032235A3 (cs) 2001-02-20 2002-02-18 Nové pyrimidinové sloučeniny
PL02363393A PL363393A1 (en) 2001-02-20 2002-02-18 New pyrimidine compounds
MXPA03007320A MXPA03007320A (es) 2001-02-20 2002-02-18 Nuevos compuestos de pirimidina.
IS6868A IS6868A (is) 2001-02-20 2003-07-08 Ný pýrimidínefnasambönd
BG108070A BG108070A (bg) 2001-02-20 2003-08-07 Нови пиримидинови съединения
ZA200306171A ZA200306171B (en) 2001-02-20 2003-08-08 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
NO20033679A NO20033679L (no) 2001-02-20 2003-08-19 Nye pyrimidinforbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds

Publications (1)

Publication Number Publication Date
SE0100569D0 true SE0100569D0 (sv) 2001-02-20

Family

ID=20283059

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds

Country Status (22)

Country Link
US (1) US7345050B2 (cs)
EP (1) EP1373266A2 (cs)
JP (1) JP4475869B2 (cs)
KR (1) KR20030084935A (cs)
CN (1) CN1294131C (cs)
BG (1) BG108070A (cs)
BR (1) BR0206935A (cs)
CA (1) CA2434648A1 (cs)
CZ (1) CZ20032235A3 (cs)
EE (1) EE200300400A (cs)
HU (1) HUP0303254A2 (cs)
IL (1) IL156781A0 (cs)
IS (1) IS6868A (cs)
MX (1) MXPA03007320A (cs)
NO (1) NO20033679L (cs)
NZ (1) NZ526783A (cs)
PL (1) PL363393A1 (cs)
RU (1) RU2003121307A (cs)
SE (1) SE0100569D0 (cs)
SK (1) SK10252003A3 (cs)
WO (1) WO2002065979A2 (cs)
ZA (1) ZA200306171B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
US20080214560A1 (en) * 2005-10-03 2008-09-04 Astrazeneca Ab Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
ATE446294T1 (de) * 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
AU2008210455A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AU2009228765B2 (en) * 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
US20120077813A1 (en) 2009-04-15 2012-03-29 Astrazeneca Ab Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR102414221B1 (ko) 2020-08-04 2022-06-27 서울시립대학교 산학협력단 열전 소자 어셈블리, 이의 제조 방법, 및 이를 포함하는 열전 모듈

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29032E (en) * 1969-06-12 1976-11-09 Riker Laboratories, Inc. 3-Benzoylfluoro-methanesulfonanilides
FR2179493A1 (en) * 1972-04-10 1973-11-23 Roussel Uclaf Amino benzhydrols - choleretics anticonvulsants sedatives and barbiturate potentiators
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
TW225528B (cs) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
RU2003121307A (ru) 2005-02-27
NZ526783A (en) 2005-04-29
CA2434648A1 (en) 2002-08-29
HK1070071A1 (en) 2005-06-10
NO20033679D0 (no) 2003-08-19
PL363393A1 (en) 2004-11-15
NO20033679L (no) 2003-08-19
BG108070A (bg) 2004-07-30
SK10252003A3 (sk) 2004-02-03
EP1373266A2 (en) 2004-01-02
EE200300400A (et) 2003-12-15
IS6868A (is) 2003-07-08
US7345050B2 (en) 2008-03-18
CZ20032235A3 (cs) 2004-01-14
CN1537112A (zh) 2004-10-13
IL156781A0 (en) 2004-02-08
WO2002065979A2 (en) 2002-08-29
JP2004527486A (ja) 2004-09-09
ZA200306171B (en) 2004-11-08
MXPA03007320A (es) 2003-12-04
CN1294131C (zh) 2007-01-10
HUP0303254A2 (hu) 2004-01-28
US20040077642A1 (en) 2004-04-22
JP4475869B2 (ja) 2010-06-09
BR0206935A (pt) 2004-06-29
WO2002065979A3 (en) 2003-02-20
KR20030084935A (ko) 2003-11-01

Similar Documents

Publication Publication Date Title
SE0100569D0 (sv) New compounds
SE0200979D0 (sv) New compounds
TW200745111A (en) New compounds
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
TW200510375A (en) New compounds
UY27368A1 (es) Nuevos compuestos
SE0102439D0 (sv) New compounds
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
BR0211473A (pt) Novos compostos
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
GB0003154D0 (en) Novel compounds
BR0211472A (pt) Novos compostos
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
SE0102440D0 (sv) New compound
SE0102055D0 (sv) New Compounds
SE0104331D0 (sv) Novel compounds
SE0101322D0 (sv) Novel compounds
SE0401655D0 (sv) New compounds
ATE253359T1 (de) Antithrombotische mittel
TW200800984A (en) New compounds
SE0102057D0 (sv) New Salts I
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
ATE286395T1 (de) Antithrombotische mittel